CMPS Soars As White House Order Supercharges Psychedelic Policy

COMPASS Pathways Plc stocks have been trading up by 5.46 percent after promising clinical trial progress boosted investor optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CMPS

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Shares of COMPASS Pathways Plc (CMPS) spiked between roughly 42% and 49% on heavy volume after a U.S. executive order to speed access to treatments for serious mental illness.
The company is pushing a rolling FDA NDA submission for COMP360 psilocybin in treatment-resistant depression, backed by two positive Phase 3 trials and late-stage PTSD work.
A new White House executive order calls for faster research, review, and rescheduling of psychedelic treatments, plus $50M in ARPA-H funding and potential priority vouchers, which CMPS publicly welcomed.
A U.S. grant program will fund external groups to build post-approval training for providers to deliver COMP360 psilocybin treatment in treatment-resistant depression.
A collaboration with Osmind and its 1,000+ clinic network aims to design real-world delivery frameworks for COMP360, supporting commercialization and scalability if FDA approval comes.

Weekly Update Apr 20 – Apr 24, 2026: On Friday, April 24, 2026 COMPASS Pathways Plc stock [NASDAQ: CMPS] is trending up by 5.46%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Compass Pathways (CMPS) sits as a leading pure‑play in psychedelic psychiatry, moving from a clinical story toward a late‑stage regulatory one. Fundamentals remain deeply loss‑making, with Q3 2025 net income of -$138m and EBITDA of -$136.5m, driving ROIC of -67.6% and large accumulated deficits (-$744m retained earnings). However, the balance sheet is still serviceable: ~$186m cash, positive working capital (~$45m), modest debt (~$35m total) and book value per share of ~$4 against an enterprise value near $1.07bn.

Technically, CMPS is in a short‑term uptrend after a sharp policy‑driven re‑rating. This week’s tape shows a rebound from an 8.65 low to a 9.65 close, with higher lows and strong volume coinciding with the executive‑order headlines, suggesting institutional participation rather than a retail-only spike. Intraday 5‑minute action has shown repeated support building near 9.00. Tactically, 9.00 is the key trading pivot: above it, long bias is warranted; a decisive break below signals exit or tight risk reduction.

More Breaking News

Catalysts are unusually strong versus the broader Healthcare and Biotechnology & Life Sciences cohorts: two positive phase 3 trials in treatment‑resistant depression, a rolling NDA, a favorable White House executive order, and commercial groundwork via Osmind and provider‑training grants. Peers remain earlier‑stage or less aligned with policy momentum. I expect further upside as regulatory clarity firms, with near‑term resistance at 10.50–11.00 and support at 9.00; 12‑month risk‑tolerant target: 13–15.

Quick Financial Overview

CMPS is trading just under $10 after a powerful policy-driven surge. The weekly chart shows a pullback from $9.75 to $8.81 early in the week, then a strong recovery back toward $9.65. That pattern tells traders this is not a quiet biotech grind; it is a momentum tape tied to Washington headlines and regulatory sentiment.

Intraday, COMPASS Pathways Plc showed a classic expansion-and-digestion move. The stock flushed from the $10.30 premarket high down toward the low $8.80s after the open, then steadily reclaimed the $9.50–$9.65 area into the close. That intraday staircase suggests active dip-buying and short covering, with $8.80–$9.00 now acting as a near-term reference support and the $9.80–$10.30 band as the first obvious supply zone.

Fundamentally, CMPS is still in heavy build-out mode. The company posted a quarterly net loss of about $137.7M with EBITDA around -$136.5M and free cash flow near -$35.1M, so this remains a cash-burning clinical and commercialization story. On the balance sheet, cash and equivalents of roughly $185.9M against total assets of $255.6M and working capital of about $44.9M give CMPS runway, but the negative 67.55% ROIC underscores that current value is all about future COMP360 monetization and regulatory timelines.

Conclusion

For traders, CMPS now sits at the center of a rare alignment: late-stage clinical data, a rolling FDA submission, and a U.S. policy shift that directly favors psychedelic therapies. The White House executive order to accelerate access, along with $50M in ARPA-H funding and possible priority vouchers, compresses perceived regulatory risk and helps explain why COMPASS Pathways Plc could rally nearly 50% in a single session. The follow-through collaboration with Osmind and the grant program for post-approval training both signal that management is not just chasing a trial win; they are building the delivery rails in advance.

From here, the key battleground for CMPS traders is whether price can hold above the mid-$9 area and attack the $10–$10.30 zone on renewed volume. The tape is clearly headline-sensitive, and the company still runs sizable quarterly losses, so swings will be sharp in both directions. For short-term players, that means respecting levels and liquidity first, story second. As I tell my students worldwide, “The edge is never in the headline itself — it’s in how you read the reaction, define your levels, and manage risk when everyone else is chasing the story.” That’s why I also remind them that headline-driven names like CMPS demand disciplined habits: as Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.”

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!